Silicon Valley Metabolic Psychiatry

About Dr. Sethi Dalai

Dr. Sethi Dalai is the founder and medical director of Silicon Valley Metabolic Psychiatry, a new center in the Bay Area focused on optimizing brain health by integrating low carb nutrition, comprehensive psychiatric care, and treatment of obesity with associated metabolic disease. She is clinical faculty at Stanford University School of Medicine, where she started the Metabolic Psychiatry Clinic in the Department of Psychiatry and Behavioral Sciences. With expertise in obesity medicine and adult eating disorders, Dr. Sethi Dalai received her MD from Duke University School of Medicine, Masters in Biotechnology from Johns Hopkins University, and completed her residency training in Psychiatry at Stanford, where she created the adult eating disorders training pathway for future resident physicians.

Dr. Sethi Dalai is currently the principal investigator of a study on the effectiveness of a low-carbohydrate dietary intervention in an outpatient cohort of patients with obesity and bipolar illness or schizophrenia; she was awarded a grant by the Obesity Treatment Foundation to support this research. She is also a co-investigator on a clinical trial testing an FDA approved obesity medication for binge-eating disorder and bulimia nervosa at Stanford University, funded by SPARK at Stanford School of Medicine. Dr. Sethi Dalai won the national Symonds Fellow Award from the Association of Women Psychiatrists for innovation and leadership in psychiatry and contributions to women’s health. She is a member of the Obesity Medicine Association, American Psychiatric Association, and served on the executive council of the Northern California Psychiatric Association. 

Honors & Awards

· Obesity Treatment Foundation Grant Award, Obesity Medicine Association (2018)

· Symonds Fellow Award, Association of Women Psychiatrists (2016)

· ASCP Clinical Trial Scholarship, American Society of Clinical Psychopharmacology (2016)

· Recipient, The Coaching Fellowship (2015)

· Scholar, Stanford Society of Physician Scholars (2015)

· Clinical and Translational Science Award (CTSA) Seed Grant, Stanford Office of Community Health (2010-2012)

Professional Education & Training 

· Residency, Stanford University Medical Center, Psychiatry (2017)

· Internship, Stanford University Medical Center, Psychiatry (2014)

· M.D., Duke University School of Medicine, Medicine (2013)

· M.S., Johns Hopkins University, Biotechnology (2007)

Select Clinical Trials Research

· Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Schizophrenia or Bipolar Illness 

· Stanford University Trial Site

· FDA Approved Medication to Reduce Binge Eating and/or Purging 

Select Global, National, and Local Presentations 

The Challenges of Treating Obesity and Comorbid Binge Eating, San Francisco, APA (American Psychiatric Association) - 2019

Treating Eating Disorders In The Community Setting, Momentum Mental Health, San Jose, CA - 2018

Repurposing Qsymia for Binge Eating Disorder and Bulimia Nervosa, Grand Rounds Department of Psychiatry, Stanford University School of Medicine - 2017

Neuroscience of Binge Eating Disorder, Department of Psychiatry, Stanford, CA - 2017

Eating Disorders Overview, Department of Psychiatry, Stanford, CA - 2017

Obesity and Mental Illness: Tipping the Scales - A Review of Weight Gain and Antipsychotics and Proposed Treatment, Global Summit on Obesity & Diet Management, Los Angeles, CA. - 2016

Select Papers and Abstracts

Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa.

Dalai SS, Adler S, Najarian T, Safer DL, Contemp Clin Trials 2018 Jan

Randomized Double-Blinded Crossover Trial Of Phentermine-Topiramate ER Versus Placebo To Treat Binge Eating Disorder And Bulimia Nervosa. Safer DL, Adler S, Sethi Dalai S, Bentley J, Najarian T, American Psychiatric Association, New York, NY - 2018

A Randomized Double-Blinded Clinical Trial Comparing Qsymia (phentermine-topiramate) Versus Placebo In Patients With Binge Eating Disorder And Bulimia. Sethi Dalai S, M.D. MS, Adler S, Psy.D, Toyama H, M.S., Safer D, M.D., American Psychiatric Association (APA), Atlanta, GA - 2016

Qsymia for Binge Eating Disorder and Bulimia Nervosa: Protocol And Preliminary Results From A Randomized, Double-Blind Cross-Over Study. Safer DL, Adler S, Sethi Dalai S, Toyama H, Fowler, Eating Disorder Research Society (EDRS), New York, NY - 2016

The Relationship Between Food Addiction and Obsessive Compulsive Behavior is Best Predicted by Binge Eating Severity. Toyama H, Fowler N, Pajarito S, Adler S, Sethi Dalai S, Safer DL, Eating Disorder Research Society (EDRS), New York, NY - 2016

Silicon Valley Psychiatry.jpeg